Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

08 representing two different revenue streams from the Shire agreement. Upon signing the agreement, Amicus received an upfront payment of $50 million that will be recognized as revenue on a straight-line basis over 18 years from the date of the agreement. In the third quarter 2008, Amicus recognized $0.7 million of the Shire upfront payment and $3.0 million of research revenue on reimbursed research and development costs.

Amicus today reiterated its most recent guidance for 2008 cash burn of $40 million to $50 million. The Company also reiterated that it does not expect to raise cash from any equity financings in 2008.

The differences between U.S. GAAP and non U.S. GAAP financial results are itemized in Tables 2 and 3, and are primarily due to pre-tax stock compensation expense

Use of Non-GAAP Financial Measures

Amicus' "non-GAAP net loss" and "non-GAAP diluted net loss per common share" financial measures are defined as reported, or GAAP, net loss and diluted net loss per common share excluding certain items further discussed below. Amicus' management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of Amicus from year to year and quarter to quarter. Accordingly, Amicus believes investors' understanding of Amicus' financial performance is enhanced as a result of disclosing these non-GAAP financial measures. Non-GAAP net loss and diluted net loss per common share should not be viewed in isolation or as a substitute for reported, or GAAP net loss and diluted net loss per common share.

(1) Stock option expense -- Non-GAAP net loss and diluted net loss per

common share exclude the impact of the stock option expense recorded

in accordance with SFAS No. 123R. Amicus believes that excluding the

impact of expensing stock options better reflects the recurring

economic characteristics of its business.

<
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... GLOBAL MARKETS , that the global market RNA interference ... nearly $38.8 billion by 2018, with a five-year compound ... category, the fastest moving segment of the market, is ... of RNAi therapeutics has shown tremendous growth and has ...
(Date:7/31/2014)... Texas (PRWEB) August 01, 2014 ... and China Polyurethane Resin Industry” is a ... Resin market. The report introduces Polyurethane Resin ... and industry chain structure and industry overview. ... including China’s domestic market as well as ...
(Date:7/31/2014)... and even the entire body to visualize long-range connections ... been a long-time dream of biologists. A study published ... journal Cell has now made that dream ... bodies, and human tissue biopsies transparent, while keeping the ... the way for a better understanding of brain-body interactions, ...
(Date:7/31/2014)... , July 31, 2014 Rogne Bioscience, ... Francisco Bay Area , has acquired a licence ... Oxford,s commercialisation company. The potent anti-inflammatory activity of the ... at the University of Oxford,s Sir William Dunn ... which has raised over $1.5 million in seed financing, ...
Breaking Biology Technology:Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4See-through organs and bodies will accelerate biomedical discoveries 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), ... http://www.cordblood-america.com ) focused on bringing the life saving ... said today that it believes the executive order signed ... of stem cell research is a significant move forward ...
... Cynvec LLC, a privately held biotechnology company focused on ... of the sindbis viral vector, today announced that Frank ... the Cowen and Company 29th Annual Health Care Conference ... p.m. ET. About Cynvec LLC , ...
... March 9 Merrimack Pharmaceuticals, Inc., a privately held ... novel treatments for cancer and autoimmune disease, today announced ... Vice President and Chief Scientific Officer and Edward (Tad) ... "Ulrik and Tad have both played critical roles ...
Cached Biology Technology:Cord Blood America Sees Significant Positives in President Obama's Lifting of Stem Cell Funding Restrictions 2Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development 2
(Date:8/1/2014)... two Simon Fraser University research associates, cite new ... collaborate closely on minimizing damage to the natural ... Maureen Ryan, David H. Smith Conservation Research Fellows ... international co-authors of the newly published research in ... , Shale gas development is the extraction of ...
(Date:7/31/2014)... prestin was found to be a key gene responsible for ... the hair cells of the inner ear that contracts and ... an antique phonograph horn, amplify sound waves to make hearing ... in the advanced online edition of Molecular Biology and ... has also independently evolved to play a critical role in ...
(Date:7/31/2014)... the National Science Foundation (NSF), counters a widely-held ... warming, indicating instead that certain Arctic lakes store ... atmosphere. , The study, published this week ... thermokarst lakes, which occur as permafrost thaws and ... water, converting what was previously frozen land into ...
Breaking Biology News(10 mins):Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3Certain Arctic lakes store more greenhouse gases than they release 2
... HOBOKEN, N.J. (June 23, 2010) An estimated 60 ... commonly known as hay fever, according to the American Academy ... allergic inflammation of the nasal airways that causes itching, swelling, ... the June 14, 2010 issue of Phytotherapy Research ...
... scientists from the University of Nevada, Reno, DRI, Arizona ... from a two-week expedition to Guatemala,s tropical high-mountain Lake ... the algae blooms that have assailed the ecosystem and ... lake,s water is contaminated with watershed runoff and waste ...
... In what is believed to be the largest review of the ... more likely to clump faster than others, scientists at Johns Hopkins ... they say likely control that bodily function. "Our results give ... from these genes, to develop tests that could help us identify ...
Cached Biology News:Study demonstrates pine bark naturally reduces hay fever symptoms 2Study demonstrates pine bark naturally reduces hay fever symptoms 3American team of scientists help protect Guatemala's Lake Atitlan 2American team of scientists help protect Guatemala's Lake Atitlan 3Genetic septet in control of blood platelet clotting 2Genetic septet in control of blood platelet clotting 3
...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
TEMPLIPHI HT SEQ AMPL KIT, 1 EA. Category: Sequencing Template Amplification....
Biology Products: